GLP-1s Are Preventing More Than Weight Gain Research is catching up with what patients are already feeling
Carry medications in original packaging with pharmacy labels, accompanied by a GP letter confirming diagnosis and medical necessity of injection devices
In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
Why is Third-Party Certification Important for Dietary Supplements
This combination provides a more complete picture of the patient's condition and supports the medical necessity of extended treatment plans
Many insurance plans require documented diet and exercise attempts, require prior authorization, or limit coverage to patients with specific comorbidities